{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:32:52Z","timestamp":1781659972691,"version":"3.54.5"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Dong-A ST Co., Ltd., Seoul, Republic of Korea","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>Growth hormone (GH) treatment is known to be effective in increasing stature in children with a short stature born small for gestational age (SGA). This multicentre, randomized, open-label, comparative, phase III study aimed to evaluate the efficacy and safety of Growtropin-II (recombinant human GH) and to demonstrate that the growth-promoting effect of Growtropin-II is not inferior to that of Genotropin in children with SGA (NCT ID: NCT02770157).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Seventy five children who met the inclusion criteria were randomized into 3 groups in a ratio of 2:2:1 (the study group [Growtropin-II, n\u200a=\u200a30], control group [Genotropin, n\u200a=\u200a30], and 26-week non-treatment group [n\u200a=\u200a15]). The study and control groups received subcutaneous injections of Growtropin-II and Genotropin, respectively for 52\u200aweeks, whereas the non-treatment group underwent a non-treatment observation period during weeks 0 to 26 and a dosing period during weeks 27 to 52 and additional dosing till week 78 only in re-consenting children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>No significant differences in demographic and baseline characteristics between the groups were observed. The mean \u00b1 standard deviation change difference in annualized height velocity (aHV) (study group - control group) was 0.65 \u00b12.12 cm\/year (95% confidence interval [CI], \u22120.53 to 1.83), whereas the lower limit for the 2-sided 95% CI was \u22120.53\u200acm\/year. Regarding safety, treatment-emergent adverse events (TEAEs) occurred in 53.33% children in the study group and 43.33% children in the control group; the difference in the incidence of TEAEs between the 2 treatment groups was not statistically significant (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.4383). A total of 17 serious adverse events (SAEs) occurred in 13.33% children in the treatment groups, and no significant difference in incidence between groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a\n                                 <jats:italic toggle=\"yes\">=<\/jats:italic>\u200a.7065) was seen. Two cases of adverse drug reaction (ADR) occurred in 2 children (3.33%): 1 ADR (injection site swelling or pain) occurred in 1 child (3.33%) each in the study and control groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study demonstrates that the change in aHV from the baseline till 52\u200aweeks with Growtropin-II treatment is non-inferior to that with Genotropin treatment in children with short stature born SGA. Growtropin-II is well-tolerated, and its safety profile is comparable with that of Genotropin over a 1-year course of treatment.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000026711","type":"journal-article","created":{"date-parts":[[2021,8,16]],"date-time":"2021-08-16T15:44:14Z","timestamp":1629128654000},"page":"e26711","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of the recombinant human growth hormone in short children born small for gestational age"],"prefix":"10.1097","volume":"100","author":[{"given":"Su Jin","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Inha University College of Medicine, Inha University Hospital, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Yoon","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Kyu","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Woo","family":"Ko","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Kyungpook National University Hospital, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Hyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University Anam Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Wook","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical Genetics Clinic and Laboratory, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong Ho","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Seoul National University Children's Hospital, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Soon","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Ajou University Hospital, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Seong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Yeong","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Inje University Busan Paik Hospital, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Jong","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chonnam National University Hospital, Gwangju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heon-Seok","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Chungbuk National University Hospital, Cheongju, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-2706","authenticated-orcid":false,"given":"Dong-Kyu","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"08","DOI":"10.1016\/j.ghir.2017.12.013","article-title":"Short children born small for gestational age outcomes in the era of growth hormone therapy","volume":"38","author":"Zanelli","year":"2018","journal-title":"Growth Horm IGF Res"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.earlhumdev.2006.07.002","article-title":"Longitudinal follow-up of height up to five years of age in infants born preterm small for gestational age; comparison to full-term small for gestational age infants","volume":"83","author":"Itabashi","year":"2007","journal-title":"Early Hum Dev"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1203\/00006450-199511000-00017","article-title":"Growth in full-term small-for-gestational-age infants: from birth to final height","volume":"38","author":"Karlberg","year":"1995","journal-title":"Pediatr Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1210\/er.2006-0039","article-title":"Small for gestational age: short stature and beyond","volume":"28","author":"Saenger","year":"2007","journal-title":"Endocr Rev"},{"key":"R5-20250504","first-page":"153","article-title":"Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis","volume":"65","author":"Cutfield","year":"2006","journal-title":"Horm Res"},{"key":"R6-20250504","first-page":"3064","article-title":"Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial","volume":"84","author":"Sas","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1297\/cpe.27.145","article-title":"Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age: final report from an open and multi-center study","volume":"27","author":"Tanaka","year":"2018","journal-title":"Clin Pediatr Endocrinol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1210\/jc.2006-2017","article-title":"Management of the child born small for gestational age through to adulthood: a consensus statement of the international societies of pediatric endocrinology and the growth hormone research society","volume":"92","author":"Clayton","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/0140-6736(93)91224-A","article-title":"Fetal nutrition and cardiovascular disease in adult life","volume":"341","author":"Barker","year":"1993","journal-title":"Lancet"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1365-2265.2004.02171.x","article-title":"Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepubertal children born small for gestational age (SGA)","volume":"62","author":"Arends","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/pr.2015.118","article-title":"Components of the metabolic syndrome in early childhood in very-low-birth-weight infants and term small and appropriate for gestational age infants","volume":"78","author":"de Jong","year":"2015","journal-title":"Pediatr Res"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3345\/kjp.2014.57.9.379","article-title":"Efficacy and safety of growth hormone treatment for children born small for gestational age","volume":"57","author":"Hwang","year":"2014","journal-title":"Korean J Pediatr"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"157","DOI":"10.6065\/jkspe.2011.16.3.157","article-title":"A single-arm, phase III study to assess efficacy and safety after 6-month-treatment of Eutropin (Inj. (Recombinant Human Growth Hormone) in prepubertal children with short stature due to small for gestational age","volume":"16","author":"Lee","year":"2011","journal-title":"J Korean Soc Pediatr Endocrinol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e0216927","DOI":"10.1371\/journal.pone.0216927","article-title":"Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG Growth Study","volume":"14","author":"Rhie","year":"2019","journal-title":"PLoS One"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.clinbiochem.2011.10.003","article-title":"Reference values for serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in Korean children and adolescents","volume":"45","author":"Hyun","year":"2012","journal-title":"Clin Biochem"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1210\/jc.2002-021172","article-title":"Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial","volume":"88","author":"Van Pareren","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1515\/JPEM.2008.21.5.423","article-title":"Efficacy and safety of growth hormone treatment in children born small for gestational age in Japan","volume":"21","author":"Tanaka","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R18-20250504","doi-asserted-by":"crossref","DOI":"10.1530\/EC-18-0286","article-title":"Growth hormone therapy in children born small for gestational age: results from the ANSWER program","author":"Rapaport","year":"2018","journal-title":"Endocr Connect"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF03346369","article-title":"Recombinant human growth hormone for children born small for gestational age: meta-analysis confirms the consistent dose-effect relationship on catch-up growth","volume":"31","author":"Crabbe","year":"2008","journal-title":"J Endocrinol Invest"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2265.2003.01905.x","article-title":"GH treatment and its effect on bone mineral density, bone maturation and growth in short children born small for gestational age: 3-year results of a randomized, controlled GH trial","volume":"59","author":"Arends","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1046\/j.1365-2265.2001.01178.x","article-title":"Carbohydrate metabolism during long-term growth hormone treatment in children with short stature born small for gestational age","volume":"54","author":"Sas","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R22-20250504","first-page":"40","article-title":"Bone age progression during the first year of growth hormone therapy in pre-pubertal children with idiopathic growth hormone deficiency, Turner syndrome or idiopathic short stature, and in short children born small for gestational age: analysis of data from KIGS (Pfizer International Growth Database)","volume":"63","author":"Darendeliler","year":"2005","journal-title":"Horm Res"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000502739","article-title":"Current insights into the role of the growth hormone-insulin-like growth factor system in short children born small for gestational age","volume":"92","author":"Renes","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"R24-20250504","first-page":"463","article-title":"Small for gestational age (SGA): endocrine and metabolic consequences and effects of growth hormone treatment","volume":"17","author":"Hokken-Koelega","year":"2004","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1007\/s13554-014-0014-4","article-title":"One-year data from a long-term phase IV study of recombinant human growth hormone in short children born small for gestational age","volume":"4","author":"Schwarz","year":"2014","journal-title":"Biol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026711","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T05:33:19Z","timestamp":1746336799000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000026711"}},"subtitle":["A randomized, multicentre, comparative phase III trial"],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":25,"journal-issue":{"issue":"30","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000026711","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"assertion":[{"value":"2021-01-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}